



# ASH 2023

## 65th ASH Annual Meeting and Exposition

December 9–12, 2023  
San Diego, US



## TOP ABSTRACTS

To help navigate the exciting content being presented at the 65th ASH Annual Meeting and Exposition, we have provided recommendations for the top abstracts to look out for in GvHD.

# ASH 2023: Top abstracts in GvHD

December 9–12, 2023

GvHD prophylaxis and early phase trials	
Abstract	Title
<b>1</b> <a href="#">View</a>	Safety and efficacy of axatilimab at 3 different doses in patients with chronic graft-versus-host disease (AGAVE-201)
<b>59</b> <a href="#">View</a>	TIM-3 inhibitor sibatolimab for patients with acute myeloid leukemia (AML) with measurable residual disease (MRD) Detected after Allogeneic Stem Cell transplantation (AlloSCT): preliminary findings from the phase Ib/II stimulus-AML2 study
<b>237</b> <a href="#">View</a>	Relapse incidence post unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide (PTCy) versus conventional anti-graft versus host disease prophylaxis in patients with acute myeloid leukemia: a study on behalf of the acute leukemia working party of the european society for blood and marrow transplantation
<b>649</b> <a href="#">View</a>	Effective prevention of steroid-requiring chronic graft-vs.-host disease with B cell depletion: a randomized, placebo-controlled trial
<b>651</b> <a href="#">View</a>	Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome with T-cell replete peripheral blood haploidentical transplantation
<b>653</b> <a href="#">View</a>	Maintenance ruxolitinib is associated with low rates of chronic Gvhd requiring systemic treatment in older adults with AML/MDS undergoing allogeneic HCT: results of a phase II multicenter trial
<b>775</b> <a href="#">View</a>	A phase II multicenter trial of ruxolitinib to treat bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation
<b>777</b> <a href="#">View</a>	Topical ruxolitinib for chronic cutaneous GvHD: promising results of a phase 2 clinical trial
<b>2103</b> <a href="#">View</a>	Updated findings of a phase II study of ruxolitinib pre-, during- and post-hematopoietic stem cell transplantation for patients with primary or secondary myelofibrosis
<b>2179</b> <a href="#">View</a>	Post-transplant cyclophosphamide or ATG as Gvhd prophylaxis in mismatched unrelated stem cell transplantation? – a registry analysis by the EBMT transplant complications working party
<b>2181</b> <a href="#">View</a>	Post-transplant cyclophosphamide, tacrolimus or cyclosporine a and mycophenolate mofetil compared to anti-thymocyte globulin, tacrolimus or cyclosporine a and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: a study on behalf of the acute leukemia working party of the European Society for Blood and Marrow Transplantation

<b>4947</b> <b>View</b>	A multicentre, randomized, double-blinded, phase 2b study evaluating the efficacy and safety of MaaT033, an oral, pooled microbiome ecosystem therapy in patients undergoing allogeneic hematopoietic cell transplantation to improve overall survival: the Phoebus trial
<b>4975</b> <b>View</b>	Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis in HLA-matched and haploidentical donor transplants for patients with hodgkin disease: a comparative study of the LWP EBMT
<b>3551</b> <b>View</b>	A prospective randomized clinical trial comparing a calcineurin-free Gvhd prophylaxis regimen with post-transplant cyclophosphamide and abatacept to methotrexate and tacrolimus

## Late phase trials

Abstract	Title
<b>654</b> <b>View</b>	Ruxolitinib in patients with chronic graft-versus-host disease: 3-year final analysis of efficacy and safety From the phase III REACH3 study

## Novel therapies

Abstract	Title
<b>3553</b> <b>View</b>	Pooled fecal allogeneic microbiotherapy for refractory gastrointestinal acute graft-versus-host disease: results from early access program in Europe
<b>3556</b> <b>View</b>	A prospective, multi-center, randomized, controlled clinical trial to explore the role of mesenchymal stem cells in preventing graft versus host disease
<b>3563</b> <b>View</b>	Efficacy and safety of processed amniotic fluid (paf) drops for the treatment of ocular chronic graft-versus-host disease
<b>3569</b> <b>View</b>	Efficacy and safety of fecal microbiota transplantation in the treatment of chronic steroid-refractory graft-versus-host disease after hematopoietic stem cell transplantation
<b>4927</b> <b>View</b>	Real-world data suggest effectiveness of allogeneic mesenchymal stromal (MSC-FFM) cells in ruxolitinib-refractory acute graft-versus-host disease
<b>4977</b> <b>View</b>	UM171 expanded cord blood transplantation outcomes compare favorably to all different stem cell sources: an EBMT registry case-control analysis

Risk stratification	
Abstract	Title
<b>479</b> <a href="#">View</a>	Machine learning validates risk biomarkers of chronic graft-versus-host disease in 936 patients from BMT CTN 0201 & 1202 cohorts
<b>652</b> <a href="#">View</a>	Systematic prediction of minor histocompatibility antigens to inform GvHD outcomes after allogeneic stem cell transplantation
<b>2191</b> <a href="#">View</a>	The area under tacrolimus concentrations on Day 14-28 is the independent predictor of the development of chronic Gvhd in patients without severe acute Gvhd after unrelated allogeneic HSCT
<b>2196</b> <a href="#">View</a>	Artificial intelligence (AI) based, machine learning (ML) predicting the individual absolute risk of acute graft versus host disease (aGvHD) in a retrospective international cohort
<b>3576</b> <a href="#">View</a>	The MAGIC algorithm probability predicts long-term outcomes and treatment response to second-line therapy for acute Gvhd

Advances in disease biology and clinical trial methodology	
Abstract	Title
<b>Scientific Symposia</b> <a href="#">View</a>	Microbiota's impact on stem cell transplant outcomes and GVHD
<b>776</b> <a href="#">View</a>	Flares of acute graft-versus-host disease: Mount Sinai Acute Gvhd International Consortium (MAGIC) study
<b>779</b> <a href="#">View</a>	A Day 14 endpoint for acute Gvhd clinical trials
<b>2043</b> <a href="#">View</a>	Intestinal geographical pattern of gut microbiome and metabolites identifies novel regulators of graft-versus-host disease



## ASH 2023

Follow us on X to keep up to date with the latest from the congress

**@gvhd\_hub**

**#ASH23**

**View all @gvhd\_hub\_tweets from #ASH23**



Brought to you by

